LL 37 Results Timeline: What Studies Measured, and When

LL-37 is the only human cathelicidin-derived antimicrobial peptide, generated from the hCAP18 precursor and studied for decades as part of innate immunity. When people look for a "results timeline", the underlying question is usually how quickly something changes after LL-37 is present. The published literature answers that question in a fragmented way: in vitro work measured killing kinetics over minutes to hours, animal models measured infection and healing endpoints over days to weeks, and human studies mostly measured endogenous LL-37 as a biomarker rather than administering it. This page maps those timepoints as they were reported.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any health decision. Nothing here describes a protocol, and no timeline below should be read as a prediction of what any individual would experience.

The Honest Starting Point: Human Administration Timelines Are Thin

There is no body of controlled human trials in the verified literature below that administered LL-37 to people and tracked outcomes at 4, 8 and 12 weeks. The human-subject data that exists measured LL-37 concentrations as an output — a marker that rose or fell — rather than as an intervention with a dosing schedule. Readers should treat every animal and laboratory timeline on this page as preclinical, clearly labelled as such, and not as a human timeline.

Two human-facing examples illustrate the difference. Researchers measuring acute salivary antimicrobial peptide secretion across different exercise intensities and durations reported responses on the timescale of a single exercise bout, sampling around the session itself (PMID 39155711). Separately, a randomised controlled trial of weekly vitamin D supplementation in children with atopic dermatitis measured disease severity and type 2 immunity biomarkers over a supplementation period, using vitamin D as the upstream lever on the cathelicidin pathway rather than giving LL-37 directly (PMID 38483248).

Minutes to Hours: What Laboratory Studies Measured First

The earliest timepoints in LL-37 research are microbiological. In vitro antimicrobial assays typically read out within hours, measuring minimum inhibitory concentrations, time-kill curves, and membrane disruption.

Antimicrobial killing assays

A 2024 study of LL-37-derived synthetic peptides designed for orthopaedic infections reported antimicrobial properties alongside cytotoxicity testing, the standard short-horizon pairing in which killing and host-cell tolerance are assessed in the same experimental window (PMID 39200064). A 2026 medicinal-chemistry report on an LL-37-derived peptide described antimicrobial potential against multidrug-resistant pathogens, again characterised in laboratory assays rather than in patients (PMID 41485275).

Engineered delivery systems

Some short-timescale work aimed to control when an antimicrobial peptide becomes active. A 2025 report in Nature Biomedical Engineering described a sonosensitive diphenylalanine-based broad-spectrum antimicrobial peptide, an approach in which activity is triggered externally rather than left to passive diffusion (PMID 40316686). Trigger-based designs shift the relevant "timeline" from days of exposure to the moment of activation.

Binding and interaction studies

Molecular interaction work also sits at the short end of the timeline. A 2025 study reported that the vitamin D-inducible antimicrobial peptide LL-37 binds SARS-CoV-2 Spike and the accessory proteins ORF7a and ORF8, a binding characterisation performed in molecular and cellular systems rather than a clinical endpoint measured over weeks (PMID 41064641).

Hours to Days: Cellular and Immune Readouts

A second tier of LL-37 research concerns immune cell behaviour, where readouts land between hours and days. A 2022 review in Cells discussed LL-37 as a multi-faceted amphipathic peptide involved in NETosis — the process by which neutrophils release extracellular traps — placing part of LL-37's biology on the timescale of acute neutrophil activation (PMID 35954305).

Clinical-sample work has used similar readouts. Investigators examining neutrophil functions in patients with neutropenia due to glycogen storage disease type 1b treated with empagliflozin assessed neutrophil function in treated patients, an approach that samples immune-cell behaviour rather than tracking a peptide dose-response curve (PMID 38531056). And a 2020 infection study reported that the efficacy of antigonococcal CMP-nonulosonate therapeutics required cathelicidins, meaning the treatment effect depended on host cathelicidin presence rather than on an administered LL-37 schedule (PMID 32692363).

Days: Animal Wound and Infection Models

Where a genuine multi-day timeline exists in LL-37 research, it is almost entirely in animal models.

MRSA wound infection

A 2021 study evaluated the efficacy of cathelicidin LL-37 in an MRSA wound infection mouse model, the classic design in which bacterial burden and wound appearance are assessed across serial post-infection days (PMID 34680791). Readers should note the species: these were mice, with controlled inoculation and controlled wound size, conditions that do not map onto human clinical timelines.

Diabetic wound healing scaffolds

A 2023 study reported that nanofiber aerogels with precision macrochannels combined with LL-37-mimic peptides synergistically promoted diabetic wound healing, a design in which the peptide is embedded in a material and healing is tracked over the model's follow-up period (PMID 36714167). Scaffold studies deliberately extend exposure, so their timelines reflect material residence time as much as peptide activity.

Weeks: Bone, Scaffold and Supplementation Horizons

The longest timelines in the verified literature belong to regenerative and supplementation contexts, where the biology itself takes weeks.

A 2024 study described an LL-37 and bisphosphonate co-delivery 3D scaffold with antimicrobial and antiresorptive activities for bone regeneration, combining a peptide with an antiresorptive agent in a construct intended for bone-healing timescales (PMID 39059543). Bone remodelling endpoints are inherently slower than bacterial-killing endpoints, which is why these studies run far longer than in vitro assays.

On the human side, the weekly vitamin D supplementation randomised controlled trial in children with atopic dermatitis measured severity and type 2 immunity biomarkers over a supplementation course, rather than measuring an LL-37 injection response (PMID 38483248). This is the closest the verified set comes to a multi-week human timeline, and it is a supplementation trial acting upstream of the cathelicidin pathway.

Timeline Summary Table

Why "Week 4, Week 8, Week 12" Does Not Map Cleanly to LL-37

Several structural features of this literature explain the absence of a conventional week-by-week schedule:

• Different endpoints run on different clocks. Bacterial killing measured in laboratory assays (PMID 41485275) and bone regeneration measured in scaffold studies (PMID 39059543) are not comparable timelines.
• Much of the work uses derivatives, not native LL-37. Synthetic LL-37-derived peptides were characterised separately from the parent molecule (PMID 39200064).
• Delivery format dominates exposure time. Aerogel and scaffold formats extend contact duration by design (PMID 36714167).
• Human data is largely biomarker-based. Salivary sampling around exercise captured acute shifts rather than a treatment course (PMID 39155711).

Tolerability and Adverse Events: What Studies Report

Cytotoxicity, not systemic side-effect reporting, is the dominant safety readout in this literature, and it appears at the same early timepoints as antimicrobial testing. The 2024 orthopaedic-infection study explicitly paired antimicrobial properties with cytotoxicity assessment of LL-37-derived synthetic peptides, reflecting the known concern that cationic amphipathic peptides can affect host cells as well as microbes (PMID 39200064). Researchers developing LL-37-derived candidates against multidrug-resistant pathogens likewise characterised the peptide in laboratory systems before any clinical claim (PMID 41485275).

On the immunological side, the 2022 review noted LL-37's involvement in NETosis, a pathway with relevance to inflammation and autoimmunity as well as host defence (PMID 35954305). Because there is no verified human administration trial here, no adverse-event frequency, severity grading or onset timeline can responsibly be stated.

How to Read Any LL-37 Timeline Claim

1. Check the species. The MRSA wound study was conducted in mice (PMID 34680791).
2. Check the molecule. Derivatives and mimics are not native LL-37 (PMID 36714167).
3. Check whether LL-37 was given or measured. In the vitamin D trial, LL-37 biology was approached indirectly through supplementation (PMID 38483248).
4. Check dependency effects. Cathelicidins were reported as required for another therapeutic's efficacy, which is a different claim from LL-37 producing an effect on its own (PMID 32692363).

Taken together, the verified literature described short-horizon antimicrobial and binding readouts (PMID 41064641), multi-day animal infection endpoints (PMID 34680791), and multi-week regenerative and supplementation endpoints (PMID 39059543) — but not a validated human results timeline. Readers seeking foundational background can review the LL-37 overview at /learn/ll-37/.

References

• A sonosensitive diphenylalanine-based broad-spectrum antimicrobial peptide (Nature Biomedical Engineering, 2025)
• Acute salivary antimicrobial peptide secretion response to different exercise intensities and durations (American Journal of Physiology. Regulatory, Integrative and Comparative Physiology, 2024)
• Neutrophil functions in patients with neutropenia due to glycogen storage disease type 1b treated with empagliflozin (Blood Advances, 2024)
• Antimicrobial Properties and Cytotoxicity of LL-37-Derived Synthetic Peptides to Treat Orthopedic Infections (Antibiotics, 2024)
• Efficacy of Antigonococcal CMP-Nonulosonate Therapeutics Require Cathelicidins (The Journal of Infectious Diseases, 2020)
• Effect of weekly vitamin D supplementation on the severity of atopic dermatitis and type 2 immunity biomarkers in children: A randomized controlled trial (JEADV, 2024)
• LL-37-derived peptide shows promising antimicrobial potential against multidrug-resistance pathogens (European Journal of Medicinal Chemistry, 2026)
• Efficacy of Cathelicidin LL-37 in an MRSA Wound Infection Mouse Model (Antibiotics, 2021)
• Nanofiber Aerogels with Precision Macrochannels and LL-37-Mimic Peptides Synergistically Promote Diabetic Wound Healing (Advanced Functional Materials, 2023)
• Vitamin D-inducible antimicrobial peptide LL-37 binds SARS-CoV-2 Spike and accessory proteins ORF7a and ORF8 (Frontiers in Cellular and Infection Microbiology, 2025)
• LL-37 and bisphosphonate co-delivery 3D-scaffold with antimicrobial and antiresorptive activities for bone regeneration (International Journal of Biological Macromolecules, 2024)
• LL-37, a Multi-Faceted Amphipathic Peptide Involved in NETosis (Cells, 2022)